Eisai Co., Ltd. receives Investment Bank Analyst Rating Update
(This May 11 story has been corrected to change some wording in the quote by Dr. Mafi in paragraph 15) By Deena Beasley (Reuters) - Wide coverage of Alzheimer's drug Leqembi would...
By Deena Beasley (Reuters) - Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to...
Biogen stock is getting favorable ratings after successful trial results for its latest Alzheimer's treatment Lecanemab is Biogen's latest attempt to cure the disease after its...
Fed week is here and, once again, analysts expect Chairman Jerome Powell and company to stay the course on rates and stimulus. For now, at least. Last week’s sizzling May...
Xencor, Inc. (NASDAQ:XNCR) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares...
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
|Moving Averages||Strong Buy||Strong Buy||Strong Buy||Buy||Strong Sell|
|Technical Indicators||Neutral||Strong Buy||Strong Buy||Strong Buy||Strong Sell|
|Summary||Buy||Strong Buy||Strong Buy||Strong Buy||Strong Sell|